Business Wire

DOLE

20.12.2022 17:17:38 CET | Business Wire | Press release

Share
Dole Releases 2022 Sustainability Report, Outlining Its Sustainability Strategy and 2030 Goals

Dole plc (NYSE: DOLE) announced today the release of its first sustainability report since the 2021 merger of Total Produce plc and Dole Food Company. Building on its historical achievements, this report sets out the organization’s refreshed sustainability framework and offers a new set of environmental, social and governance (ESG) goals through 2030.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221220005564/en/

The Dole Way, Dole’s sustainability framework, focuses on robust governance and three core pillars—For Nature, For People and For Food—covering environmental, ethical and social and nutrition related issues. These three pillars incorporate key areas identified as being most material to the impact of our business’ operations.

  • For Nature: By committing to the Science Based Target Initiative, Dole plc places climate action at the forefront of its priorities along with water stewardship, biodiversity, waste management and packaging reduction and innovation.
  • For People: Directly employing 38,500 people globally while partnering with third party growers worldwide, Dole is committed to being an employer of choice, supporting local communities and protecting human rights across its supply chains.
  • For Food: Dole is committing to promoting healthy nutrition and improving access to fresh produce through partnerships and donations.

“Dole has built market-leading positions across a wide range of fresh fruit and vegetable segments by incorporating sustainability into their growth models,” stated Rory Byrne, Dole plc Chief Executive Officer. “As our climate is changing, we are focused on identifying the related risks, adapting to the effects on our operations and minimizing our own impacts. We also recognize and relish the special role we can play in improving people’s lives and the contribution Dole can make to promoting good health and wellbeing.”

The report also lays the foundation for the promotion of regenerative farming practices across Dole’s own operations as well as on associated farms which will support the business’ ambitious climate goals.

Highlights of the report include Dole plc’s:

  • First global carbon footprint collection including measuring and managing scope 1, scope 2 and scope 3 emissions resulting in a reduction of 4% in Scope 1 and 2 emissions (2021 over 2020)
  • Investment in Renewal Energy with two 2.8 megawatt wind turbines in Dole Fresh Vegetables in Soledad, California and installed new solar panel system at Belfast, Ireland site with a capacity of 120 kWp
  • Recognition by American-Costa Rican Chamber of Commerce (AmCham) of Dole affiliate, Standard Fruit Company de Costa Rica S.A., for their innovative project "De la Mano con Dole." The project positively impacts the social development of employees and their families using the Business Multidimensional Poverty Index (bMPI) methodology which measures poverty beyond only per capita income - to include access to health, education, housing, work, social protection and 16 other key indicators.

Xavier Roussel, Dole plc’s Chief Marketing and Sustainability officer, stated, “Although fresh produce has a low environmental footprint in comparison to other food sources, there is still much to do to further decrease our impacts and adapt to the effects of climate change. We are addressing those challenges for the long term with likeminded partners along the supply chain. Our vertically integrated business model allows us to research much in our own operations before expanding to our associated farmers which is instrumental to lead change in the industry.”

Adding, “Caring for our most important resources: our people, the nature around us and the food we deliver to the world is our way to contribute to society and will set us up for continued success.”

To view the full Dole plc 2022 Corporate Responsibility & Sustainability Report click here or visit www.doleplc.com.

About Dole plc

A global leader in fresh produce, Dole Plc grows, markets, and distributes an extensive variety of fresh fruits and vegetables sourced locally and from around the world. Dedicated and passionate in exceeding our customers’ requirements in over 75 countries, our goal is to make the world a healthier and a more sustainable place. For more information, please visit www.doleplc.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005564/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye